Review anchor
Prostaglandin G/H synthase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Prostaglandin G/H synthase 1
CHEMBL221
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin G/H synthase 1 as ChEMBL target CHEMBL221, mapped to UniProt P23219. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL221
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23219
Prostaglandin G/H synthase 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Prostaglandin G/H synthase 1 matters
Prostaglandin G/H synthase 1 is reviewed as Prostaglandin G/H synthase 1 (UniProt P23219); Prostaglandin G/H synthase 1 shows approved-linked disease relevance led by Fever. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 48 approved drugs, 5554 compounds, and 752 assays, with lead potency reaching pChEMBL 9.8.
Protein context
Prostaglandin G/H synthase 1
Prostaglandin G/H synthase 1 Sequence length is 599 aa.
Review this target as Prostaglandin G/H synthase 1, mapped to UniProt P23219. Sequence length is 599 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P23219
Protein
Disease context
Fever
Prostaglandin G/H synthase 1 shows approved-linked disease relevance led by Fever. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ANTIPYRINE.
Start review with Fever because it currently carries approved-linked support. Linked drugs include ANTIPYRINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 48 approved drugs, 5554 compounds, and 752 assays for this target. The dominant activity type is IC50. CHEMBL6 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL6 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core Engine
48 approved
pChEMBL 9.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Prostaglandin G/H synthase 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23219, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Fever is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5554
Total Compounds
752
Total Assays
48
Approved Drugs
IC50: 4397.0, KI: 840.0, EC50: 1.0, KD: 6.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL6
|
9.8 | IC50 | Approved |
|
|
No preferred name
CHEMBL143776
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL5206077
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL1945285
|
8.9 | IC50 | — |
|
|
No preferred name
CHEMBL259972
|
8.8 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
VORTIOXETINE
CHEMBL2104993
|
2013 |
|
|
LUMIRACOXIB
CHEMBL404108
|
2005 |
|
|
CELECOXIB
CHEMBL118
|
1998 |
|
|
BROMFENAC
CHEMBL1077
|
1997 |
|
|
MOFEZOLAC
CHEMBL259972
|
1994 |
|
|
DEXKETOPROFEN
CHEMBL75435
|
1994 |
|
|
DEXIBUPROFEN
CHEMBL175
|
1994 |
|
|
OXAPROZIN
CHEMBL1071
|
1992 |
|
|
ETODOLAC
CHEMBL622
|
1991 |
|
|
KETOROLAC
CHEMBL469
|
1989 |
|
|
DICLOFENAC
CHEMBL139
|
1988 |
|
|
DICLOFENAC SODIUM
CHEMBL1034
|
1988 |
|
|
CARPROFEN
CHEMBL1316
|
1987 |
|
|
FLURBIPROFEN
CHEMBL563
|
1986 |
|
|
KETOPROFEN
CHEMBL571
|
1986 |
|
|
SUPROFEN
CHEMBL956
|
1985 |
|
|
MECLOFENAMIC ACID
CHEMBL509
|
1980 |
|
|
FENOPROFEN
CHEMBL1297
|
1976 |
|
|
NAPROXEN
CHEMBL154
|
1976 |
|
|
TOLMETIN
CHEMBL1020
|
1976 |
|
|
IBUPROFEN
CHEMBL521
|
1974 |
|
|
MEFENAMIC ACID
CHEMBL686
|
1967 |
|
|
THIOGUANINE
CHEMBL727
|
1966 |
|
|
INDOMETHACIN
CHEMBL6
|
1965 |
|
|
ASPIRIN
CHEMBL25
|
1950 |
|
|
3,3',4',5-TETRACHLOROSALICYLANILIDE
CHEMBL291338
|
— |
Source Header